A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease
Status:
Completed
Trial end date:
2019-08-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group comparison study in
subjects with Alzheimer's Disease. Following first screening period, subjects will be
randomly assigned into one of the following arms: AstroStem and placebo control in a 1:1
ratio. AstroStem or placebo control will be administered via I.V. at Week 0. This procedure
will be repeated 9 times at 2-week interval. Subjects will be scheduled for two follow-up
visits at Weeks 30 and 52 to evaluate primary and secondary outcome endpoints.